Predicting deseasonalised serum 25 hydroxy vitamin D concentrations in the D-Health Trial: An analysis using boosted regression trees.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

The researchers did not have adequate statistical power for subgroup analyses, so could not justify the high cost of collecting blood samples at baseline.

To enable future exploratory analyses stratified by baseline vitamin D status, the researchers developed models to predict baseline serum 25 hydroxy vitamin D [25(OH)D] concentration.

Who Took Part

The researchers used data and serum 25(OH)D concentrations from participants who gave a blood sample during the trial for compliance monitoring and were randomised to placebo.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

The researchers fitted boosted regression tree models, based on 13 predictors, and evaluated model performance using the validation data.

What Was Measured

PubMed files the paper under topics including Calcifediol, Dietary Supplements, Vitamin D and Vitamin D Deficiency.

The authors tagged it with the keywords Boosted regression trees, Prediction model and Randomised clinical trial.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2021 (Contemporary clinical trials), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.